Table 2.
Baseline distribution of co‐morbidities among 1:1 comparative cohorts matched on sex, age group and calendar time, 2010‐2014
| T1D vs. no diabetes | T2D vs. no diabetes | |||||
|---|---|---|---|---|---|---|
| T1Da | No diabetesb | ASD T1D – No diabetesc | T2Dd | No diabetesb | ASD T2D – No diabetesc | |
| N | 120 129 | 120 129 | 1 679 877 | 1 679 877 | ||
| At cohort entry | ||||||
| Age, mean (SD) | 49.9 (18.68) | 50.0 (18.26) | 0.01 | 58.8 (12.42) | 58.4 (12.82) | 0.03 |
| Age 18‐30 y | 18.7% | 18.7% | 0 | 1.2% | 1.2% | 0 |
| Age 31‐40 y | 11.9% | 11.9% | 0 | 5.6% | 5.6% | 0 |
| Age 41‐50 y | 17.4% | 17.4% | 0 | 16.9% | 16.9% | 0 |
| Age 51‐60 y | 22.3% | 22.3% | 0 | 33.8% | 33.8% | 0 |
| Age 61‐70 y | 15.4% | 15.4% | 0 | 25.3% | 25.3% | 0 |
| Age 71‐80 y | 9.1% | 9.1% | 0 | 11.6% | 11.6% | 0 |
| Age >80 y | 5.2% | 5.2% | 0 | 5.5% | 5.5% | 0 |
| Female | 46.6% | 46.6% | 0 | 46.8% | 46.8% | 0 |
| Co‐morbidities during the baseline periode | ||||||
| Arterial hypertension | 32.9% | 16.1% | 0.40 | 44.3% | 20.9% | 0.51 |
| Atrial fibrillation | 3.9% | 1.9% | 0.12 | 3.6% | 2.3% | 0.07 |
| Ischaemic heart disease | 13.6% | 3.6% | 0.36 | 10.9% | 5.0% | 0.22 |
| Congestive heart failure | 6.4% | 1.0% | 0.29 | 3.3% | 1.1% | 0.15 |
| Cerebrovascular diseases | 4.8% | 1.5% | 0.19 | 3.5% | 1.8% | 0.10 |
| Diabetic retinopathy | 9.0% | 0.1% | 0.44 | 1.8% | 0.1% | 0.18 |
| Chronic kidney disease | 10.5% | 1.1% | 0.41 | 3.9% | 1.3% | 0.16 |
| Peripheral artery disease | 5.4% | 1.2% | 0.24 | 3.3% | 1.5% | 0.12 |
| Peripheral polyneuropathy | 4.0% | <0.1% | 0.28 | 1.4% | 0.1% | 0.16 |
| Foot deformities | 2.1% | 1.1% | 0.08 | 1.6% | 1.3% | 0.02 |
| Charcot foot | 0.3% | <0.1% | 0.08 | 0.1% | <0.1% | 0.03 |
| Preulcerative callus or corn | 1.3% | 0.2% | 0.12 | 0.7% | 0.3% | 0.06 |
| Medications anytime prior to matched indexf | ||||||
| Diuretics | 33.7% | 14.1% | 0.47 | 46.7% | 17.9% | 0.65 |
| Loop diuretics | 18.9% | 3.0% | 0.53 | 13.6% | 3.6% | 0.36 |
| Insulin | 100% | 0.1% | 48.51 | 15.8% | 0.1% | 0.61 |
Abbreviations: ASD, absolute standardized difference; T1D, type 1 diabetes; T2D, type 2 diabetes.
T1D defined as ≥1 prior inpatient or outpatient claim for T1D (ICD9: 250.x1, 250.x3) + no prior oral antidiabetic claim + ≥1 prior insulin claim.
The No diabetes cohort was defined as neither prior inpatient nor prior outpatient claims for diabetes (ICD9: 250.x) at the time of matched index and 1:1 matched to each diabetic cohort based on sex and age category (18‐30, 31‐40, 41‐50, 51‐60, 61‐70, 71‐80, >80 y).
T2D was defined as ≥2 prior inpatient or outpatient claims for T2D (ICD9: 250.x0, 250.x2) + ≥1 prior oral antidiabetic claim.
All co‐morbidities defined as at least 1 inpatient claim or at least 2 outpatient claims on 2 separate days during the 365 days prior to matched index date.
Medications defined based on at least 1 prescription claim during all available data prior to matched index date.